Joomla gallery extension by joomlashine.com
Main Promo Images
Latest news on Friedreich's Ataxia research
Updated results from clinical trials and research initiatives
Friedreich's Ataxia fundraising activities and staying in touch
Participate and stay informed about our fundraising events. Take part in our Facebook community with FA patients, relatives, researchers and friends from all around the world!
Translation: Diego Plaza González and Tom Sathre
Brudy Technology - Spain
July 10 2008
A clinical trial will try to prove Algatrium Plus effective for people affected by ataxia.
The Spanish association Ataxias en Movimiento (Ataxias on the Move) is collaborating in a trial aimed at reducing oxidative stress in ataxia patients thanks to the intake of Algatrium Plus, a unique, specific DHA molecule which has proven itself effective in activating the cellular antioxidant system.
The Ataxias on the Move association is collaborating in a clinical trial in an attempt to prove the effectiveness of Algatrium Plus in patients with ataxia. This study, which started last week, is aimed at showing a reduction in oxidative damage in people affected by ataxia, so they can obtain Algatrium Plus as a treatment.
22 people are taking part in this trial, mainly Friedreich's Ataxia patients (18 of them are) and other kinds of ataxias proportionately. Participants' age ranges from 20 to 40 years, although there are one 17-year-old girl and two 62-year-old patients. The study will last for three months; in the meanwhile participants will undergo three medical analyses to check that oxidative stress is decreasing. Algatrium Plus is a safe substance since it has successfully passed the first two test phases, including the one dealing with lack of toxicity.
If after this time results are as expected, the treatment will be continued indefinitely and it will be available for all ataxia patients. According to Isabel Gonzalez from the Ataxias on the Move association: "the main point is that once results are revealed and they prove positive, conclusions will be forwarded to health authorities and institutions so that Algatrium Plus can be provided at no cost to people affected by this disease".
As Joan Carles Domingo, Ph.D. in Chemistry from the Barcelona University, person in charge of Brudy Technology's research department and coordinator of this trial, puts it, "in three months' time we expect to confirm a reduction of oxidative damage and, in the long run, a fall in all related pathologies which may touch people affected by ataxia, such as diabetes or loss of peripheral vision. We also hope to see a reduction in the severity of depressions, usually implied by diseases of this kind."
Ataxias are a condition characterized by a progressive loss of ability in coordinating body movement. It is a degenerative process which can be highly debilitating and still has no effective treatment. The Ataxias on the Move association carries an ongoing fight to eradicate this disease and improve quality of life for affected people. For Isabel González, "ataxias have never been attractive to the pharmaceutical industry, but after we received petitions from patients that were already taking Algatrium Plus on their own, we contacted Brudy Technology, whose researchers showed us their interest for genetic diseases and, above all, for advancing this project".
Regarding DHA and Brudy Technology see also:
If you feel like reading an unputdownable novel while collaborating with a just and solidary cause, "The Legacy of Marie Schlau" is your book! 100% of all funds raised will be dedicated to medical research to find a cure for Friedreich's Ataxia, a neurodegenerative disease that affects mostly young people, shortening their life expectancy and confining them to a wheelchair.
The life of Marie Schlau, a German Jewish girl born in 1833 hides great unsolved mysteries: accidents, disappearances, enigmas, unknown diagnoses, disturbing murders, love, tenderness, greed, lies, death ... alternatively a different story unfolds every time and takes us closer to the present. Thus, there are two parallel stories unravelling, each in a different age and place, which surprisingly converge in a revelatory chapter.
Paperback and Kindle versions for "The legacy of Marie Schlau" available for sale at Amazon now!
Currently, BabelFAmily is financing two promising research projects aimed at finding a cure for Friedreich's Ataxia. Whenever you make a donation to us or purchase a copy of "The legacy of Marie Schlau", this is where all funds raised will be devoted to:
1) Gene Therapy for Friedreich's Ataxia research project:
The project is the result of an initiative of Spanish people affected by this rare disease who are grouped in GENEFA in collaboration with the Spanish Federation of Ataxias and the BabelFAmily. The Friedreich’s Ataxia Research Alliance (FARA), one of the main patients’ associations in the United States now joins the endeavour.
2) Frataxin delivery research project:
The associations of patients and families Babel Family and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF) channel 80,000 euros of their donations (50% from each organisation) into a new 18-month project at the Institute for Research in Biomedicine (IRB Barcelona). The project specifically aims to complete a step necessary in order to move towards a future frataxin replacement therapy for the brain, where the reduction of this protein causes the most damage in patients with Friedreich’s Ataxia.
The study is headed by Ernest Giralt, head of the Peptides and Proteins Lab, who has many years of experience and is a recognised expert in peptide chemistry and new systems of through which to delivery drugs to the brain, such as peptide shuttles—molecules that have the capacity to carry the drug across the barrier that surrounds and protects the brain. Since the lab started its relation with these patients’ associations in 2013*, it has been developing another two projects into Friedrich’s Ataxia.